Weight changes during treatment with low-sodium oxybate in two phase 3 clinical studies in participants with narcolepsy or idiopathic hypersomnia
Open-label LXB was associated with modest weight loss in participants with narcolepsy with cataplexy or idiopathic hypersomnia.
Authors
- Marisa Whalen
- Thomas J. Measey
- Shawn Candler (ORCID: https://orcid.org/0000-0003-2348-9112)
- Teresa L. Steininger (ORCID: https://orcid.org/0009-0005-9564-0901)
- Nancy Foldvary‐Schaefer (ORCID: https://orcid.org/0000-0001-8900-3280)
- Roman Skowroński
- Douglas S. Fuller (ORCID: https://orcid.org/0000-0002-2448-5896)
- Patricia Chandler
Institutions
- Cleveland Clinic (US)
- Inserm (FR)
- Université de Montpellier (FR)
- Jazz Pharmaceuticals (United States) (US)
- Institute for Neurosciences of Montpellier (FR)
- The Neurological Institute (US)
Publication Details
- Journal
- Sleep Medicine
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1016/j.sleep.2025.106602
- Citations
- 1
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Jazz Pharmaceuticals